FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029973586> ?p ?o ?g. }

• W2029973586 endingPage "1921" @default.
• W2029973586 startingPage "1915" @default.
• W2029973586 abstract "No AccessJournal of UrologyInvestigative Urology1 May 2011Toll-Like Receptors in Normal and Malignant Human Bladders Cherifa Ayari, Alain Bergeron, Hélène LaRue, Claire Ménard, and Yves Fradet Cherifa AyariCherifa Ayari More articles by this author , Alain BergeronAlain Bergeron More articles by this author , Hélène LaRueHélène LaRue More articles by this author , Claire MénardClaire Ménard More articles by this author , and Yves FradetYves Fradet More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.12.097AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Toll-like receptors have a major role in the innate immune response. They are expressed by immune cells and some epithelial cells. To study the role of urothelial cells in the intrabladder innate immune response we analyzed toll-like receptor expression and functionality in normal and malignant urothelial cells. Materials and Methods: Toll-like receptor 1 to 10 mRNA expression was analyzed using reverse transcriptase-polymerase chain reaction in 4 primary cultures of normal urothelium and 15 bladder cancer cell lines. Immunohistochemistry was used to detect toll-like receptor expression in 11 normal urothelial samples and 26 bladder tumors. Proinflammatory cytokine secretion by toll-like receptor agonist or bacillus Calmette-Guérin treated cultured cells was assessed by enzyme-linked immunosorbent assay. Mitogen-activated protein kinase phosphorylation was analyzed by Western blot and nuclear factor-κB localization was assessed by confocal microscopy. Results: Expression of most toll-like receptor mRNA was detected in cultured normal or tumor urothelial cells. Expression of toll-like receptors 2 to 4, 5, 7 and 9 protein was detected in all normal urothelial samples and most nonmuscle invasive tumors, although its intensity was decreased in the latter. Expression was markedly decreased in muscle invasive tumors. Treatment with toll-like receptor 2 and 3 agonists showed the strongest inflammatory response in 2 primary cultures of normal urothelial cells and 3 bladder cancer cell lines. Toll-like receptor 2 and 3 functionality was confirmed by the nuclear translocation of nuclear factor-κB and the induction of phosphorylated c-Jun N-terminal kinase mitogen-activated protein-kinase. Conclusions: Toll-like receptors are expressed in normal urothelium and nonmuscle invasive bladder tumors. In cultured urothelial cells agonist inducible toll-like receptor 2 or constitutively expressed toll-like receptor 3 is functional. These data suggest the potential use of toll-like receptor agonists for antitumor immunotherapy of nonmuscle invasive tumors. References 1 : The uroepithelium: not just a passive barrier. Traffic2004; 5: 117. Google Scholar 2 : Urinary bladder urothelium: molecular sensors of chemical/thermal/mechanical stimuli. Vascul Pharmacol2006; 45: 221. Google Scholar 3 : Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer2004; 91: 607. Google Scholar 4 : Recognition of microorganisms and activation of the immune response. Nature2007; 449: 819. Google Scholar 5 : Toll-like receptors and cancer. Nat Rev Cancer2009; 9: 57. Google Scholar 6 : The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA2000; 97: 13766. Google Scholar 7 : Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother2008; 57: 1271. Google Scholar 8 : Toll-like receptor signaling in cell proliferation and survival. Cytokine2010; 49: 1. Google Scholar 9 : Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J Cancer Res Clin Oncol2009; 135: 379. Google Scholar 10 : Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest1994; 71: 583. Google Scholar 11 : MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer2007; 120: 2170. Google Scholar 12 : Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med2005; 201: 1281. Google Scholar 13 : Beta-arrestin 2 is required for lysophosphatidic acid-induced NF-kappaB activation. Proc Natl Acad Sci USA2008; 105: 17085. Google Scholar 14 : Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer. Int J Cancer1997; 71: 986. Google Scholar 15 : A toll-like receptor that prevents infection by uropathogenic bacteria. Science2004; 303: 1522. Google Scholar 16 : TLR-mediated immune responses in the urinary tract. Curr Opin Microbiol2008; 11: 66. Google Scholar 17 : TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells. Cancer Invest2008; 26: 816. Google Scholar 18 : A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells. PLoS Pathog2007; 3: e60. Google Scholar 19 : Innate and adaptive immune responses in the urinary tract. Eur J Clin Invest2008; 38: 21. Google Scholar 20 : TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol2008; 6: 40. Google Scholar 21 : Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J Physiol Pharmacol2009; 60: 65. Google Scholar 22 : Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells. Oncogene2008; 27: 225. Google Scholar 23 : Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog2007; 46: 872. Google Scholar 24 : Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol2005; 174: 86. Link, Google Scholar 25 : Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer?: A meta-analysis of randomized trials . Urology2006; 67: 1216. Google Scholar 26 : Targeting toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov2010; 9: 293. Google Scholar 27 : Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol2005; 26: 274. Google Scholar 28 : In vitro and in vivo effects of CpG-oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Anticancer Res2009; 29: 2067. Google Scholar 29 : Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol2007; 177: 2347. Link, Google Scholar 30 : Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in nonmuscle invasive bladder tumors. Clin Genitourin Cancer2009; 7: E16. Google Scholar Centre de Recherche en Cancérologie de l'Université Laval, Centre Hospitalier Universitaire de Québec-L'Hôtel-Dieu de Québec, Ville de Québec, Québec, Canada© 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 5May 2011Page: 1915-1921 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Keywordsimmunotherapytoll-like receptorsurotheliumurinary bladder neoplasmsurinary bladderAcknowledgmentsDr. Bernard Têtu, Department of Pathology, Centre Hospitalier Universitaire de Québec, provided FFPE tumor tissue. The Quebec Transplant personnel coordinated the tissue donations.MetricsAuthor Information Cherifa Ayari More articles by this author Alain Bergeron More articles by this author Hélène LaRue More articles by this author Claire Ménard More articles by this author Yves Fradet More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2029973586 created "2016-06-24" @default.
• W2029973586 creator A5002028119 @default.
• W2029973586 creator A5012815468 @default.
• W2029973586 creator A5023741697 @default.
• W2029973586 creator A5046141598 @default.
• W2029973586 creator A5075327765 @default.
• W2029973586 date "2011-05-01" @default.
• W2029973586 modified "2023-10-15" @default.
• W2029973586 title "Toll-Like Receptors in Normal and Malignant Human Bladders" @default.
• W2029973586 cites W1869191601 @default.
• W2029973586 cites W1980273234 @default.
• W2029973586 cites W1989115197 @default.
• W2029973586 cites W2000371637 @default.
• W2029973586 cites W2006469490 @default.
• W2029973586 cites W2007963505 @default.
• W2029973586 cites W2013469022 @default.
• W2029973586 cites W2016388868 @default.
• W2029973586 cites W2016862474 @default.
• W2029973586 cites W2021065674 @default.
• W2029973586 cites W2033527694 @default.
• W2029973586 cites W2034028219 @default.
• W2029973586 cites W2039218197 @default.
• W2029973586 cites W2047573521 @default.
• W2029973586 cites W2048199751 @default.
• W2029973586 cites W2053159518 @default.
• W2029973586 cites W2060313939 @default.
• W2029973586 cites W2062431830 @default.
• W2029973586 cites W2065186557 @default.
• W2029973586 cites W2079285151 @default.
• W2029973586 cites W2093585643 @default.
• W2029973586 cites W2094148727 @default.
• W2029973586 cites W2114216755 @default.
• W2029973586 cites W2116250664 @default.
• W2029973586 cites W2141568897 @default.
• W2029973586 cites W2159759416 @default.
• W2029973586 cites W2166433840 @default.
• W2029973586 doi "https://doi.org/10.1016/j.juro.2010.12.097" @default.
• W2029973586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21421234" @default.
• W2029973586 hasPublicationYear "2011" @default.
• W2029973586 type Work @default.
• W2029973586 sameAs 2029973586 @default.
• W2029973586 citedByCount "44" @default.
• W2029973586 countsByYear W20299735862012 @default.
• W2029973586 countsByYear W20299735862013 @default.
• W2029973586 countsByYear W20299735862014 @default.
• W2029973586 countsByYear W20299735862015 @default.
• W2029973586 countsByYear W20299735862016 @default.
• W2029973586 countsByYear W20299735862017 @default.
• W2029973586 countsByYear W20299735862018 @default.
• W2029973586 countsByYear W20299735862019 @default.
• W2029973586 countsByYear W20299735862020 @default.
• W2029973586 countsByYear W20299735862021 @default.
• W2029973586 countsByYear W20299735862022 @default.
• W2029973586 countsByYear W20299735862023 @default.
• W2029973586 crossrefType "journal-article" @default.
• W2029973586 hasAuthorship W2029973586A5002028119 @default.
• W2029973586 hasAuthorship W2029973586A5012815468 @default.
• W2029973586 hasAuthorship W2029973586A5023741697 @default.
• W2029973586 hasAuthorship W2029973586A5046141598 @default.
• W2029973586 hasAuthorship W2029973586A5075327765 @default.
• W2029973586 hasConcept C126322002 @default.
• W2029973586 hasConcept C142724271 @default.
• W2029973586 hasConcept C170493617 @default.
• W2029973586 hasConcept C203014093 @default.
• W2029973586 hasConcept C2778025104 @default.
• W2029973586 hasConcept C502942594 @default.
• W2029973586 hasConcept C71924100 @default.
• W2029973586 hasConcept C86803240 @default.
• W2029973586 hasConcept C95444343 @default.
• W2029973586 hasConceptScore W2029973586C126322002 @default.
• W2029973586 hasConceptScore W2029973586C142724271 @default.
• W2029973586 hasConceptScore W2029973586C170493617 @default.
• W2029973586 hasConceptScore W2029973586C203014093 @default.
• W2029973586 hasConceptScore W2029973586C2778025104 @default.
• W2029973586 hasConceptScore W2029973586C502942594 @default.
• W2029973586 hasConceptScore W2029973586C71924100 @default.
• W2029973586 hasConceptScore W2029973586C86803240 @default.
• W2029973586 hasConceptScore W2029973586C95444343 @default.
• W2029973586 hasIssue "5" @default.
• W2029973586 hasLocation W20299735861 @default.
• W2029973586 hasLocation W20299735862 @default.
• W2029973586 hasOpenAccess W2029973586 @default.
• W2029973586 hasPrimaryLocation W20299735861 @default.
• W2029973586 hasRelatedWork W2353712315 @default.
• W2029973586 hasRelatedWork W2359940423 @default.
• W2029973586 hasRelatedWork W2489749982 @default.
• W2029973586 hasRelatedWork W2757240192 @default.
• W2029973586 hasRelatedWork W3022029543 @default.
• W2029973586 hasRelatedWork W3116002356 @default.
• W2029973586 hasRelatedWork W582981267 @default.
• W2029973586 hasRelatedWork W588210059 @default.
• W2029973586 hasRelatedWork W592613903 @default.
• W2029973586 hasRelatedWork W625959138 @default.
• W2029973586 hasVolume "185" @default.
• W2029973586 isParatext "false" @default.
• W2029973586 isRetracted "false" @default.
• W2029973586 magId "2029973586" @default.

• next